NO20082026L - Deazapuriner som er nyttige som inhibitorer for Janus-kinaser - Google Patents

Deazapuriner som er nyttige som inhibitorer for Janus-kinaser

Info

Publication number: NO20082026L
Authority: NO; Norway
Prior art keywords: inhibitors; useful; deazapurins; janus kinases; kinases
Prior art date: 2005-09-30

Application number

NO20082026A

Other languages

English (en)

Norwegian (no)

Inventor

Tiansheng Wang

Jian Wang

Randy Bethiel

Gabriel Martinez-Botella

Francesco Salituro

Luc Farmer

Marion Wannamaker

John Duffy

Alexander Aronov

David Lauffer

Albert Pierce

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-30

Filing date

2008-04-29

Publication date

2008-06-25

2008-04-29 Application filed by Vertex Pharma filed Critical Vertex Pharma

2008-06-25 Publication of NO20082026L publication Critical patent/NO20082026L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)

NO20082026A 2005-09-30 2008-04-29 Deazapuriner som er nyttige som inhibitorer for Janus-kinaser NO20082026L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72256105P	2005-09-30	2005-09-30
PCT/US2006/037593 WO2007041130A2 (en)	2005-09-30	2006-09-28	Deazapurines useful as inhibitors of janus kinases

Publications (1)

Publication Number	Publication Date
NO20082026L true NO20082026L (no)	2008-06-25

Family

ID=37546336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20082026A NO20082026L (no)	2005-09-30	2008-04-29	Deazapuriner som er nyttige som inhibitorer for Janus-kinaser

Country Status (15)

Country	Link
US (1)	US8580802B2 (es)
EP (2)	EP2532667A1 (es)
JP (1)	JP2009513571A (es)
KR (1)	KR20080063809A (es)
CN (1)	CN101801971A (es)
AU (1)	AU2006297351A1 (es)
CA (1)	CA2623032A1 (es)
ES (1)	ES2401192T3 (es)
IL (1)	IL190249A0 (es)
NO (1)	NO20082026L (es)
NZ (1)	NZ567133A (es)
RU (1)	RU2008117151A (es)
SG (1)	SG151327A1 (es)
WO (1)	WO2007041130A2 (es)
ZA (1)	ZA200802685B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4937112B2 (ja) *	2004-03-30	2012-05-23	バーテックスファーマシューティカルズインコーポレイテッド	Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
EP1881983B1 (en) *	2005-05-20	2012-01-11	Vertex Pharmaceuticals, Inc.	Pyrrolopyridines useful as inhibitors of protein kinase
EP1926735A1 (en)	2005-09-22	2008-06-04	Incyte Corporation	Tetracyclic inhibitors of janus kinases
SG10201506912RA (en)	2005-12-13	2015-10-29	Incyte Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
TW200801008A (en)	2005-12-29	2008-01-01	Abbott Lab	Protein kinase inhibitors
BRPI0706537A2 (pt)	2006-01-17	2011-03-29	Vertex Pharma	azaindóis úteis como inibidores de janus cinases
US8741912B2 (en) *	2006-04-05	2014-06-03	Vertex Pharmaceuticals Incorporated	Deazapurines useful as inhibitors of Janus kinases
CA2660758A1 (en)	2006-08-24	2008-02-27	Astrazeneca Ab	Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
KR20090091350A (ko)	2006-12-21	2009-08-27	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로 유용한 ５-시아노-４-피롤로[２,３ｂ]피리딘-３-일)-피리디민 유도체
ES2415863T3 (es)	2006-12-22	2013-07-29	Incyte Corporation	Heterociclos sustituidos como inhibidores de Janus Quinasas
WO2008116139A2 (en) *	2007-03-22	2008-09-25	Vertex Pharmaceuticals Incorporated	N-heterocyclic compounds useful as inhibitors of janus kinases
SI2740731T1 (sl)	2007-06-13	2016-07-29	Incyte Holdings Coroporation	Kristalinične soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopen tilpropannitrila
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2385692T3 (es)	2007-07-09	2012-07-30	Astrazeneca Ab	Derivados de morfolino pirimidina usados en enfermedades relacionadas con mTOR quinasa y/o PI3K
CA2709710A1 (en) *	2007-12-19	2009-07-09	Vertex Pharmaceuticals Incorporated	Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
DE102008005493A1 (de) *	2008-01-22	2009-07-23	Merck Patent Gmbh	4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
SG191660A1 (en)	2008-03-11	2013-07-31	Incyte Corp	Azetidine and cyclobutane derivatives as jak inhibitors
US20110053907A1 (en) *	2008-03-27	2011-03-03	Auckland Uniservices Limited	Substituted pyrimidines and triazines and their use in cancer therapy
WO2010005048A1 (ja) *	2008-07-09	2010-01-14	日産化学工業株式会社	イソキサゾリン置換安息香酸アミド化合物の製造方法
GB2465405A (en) *	2008-11-10	2010-05-19	Univ Basel	Triazine, pyrimidine and pyridine analogues and their use in therapy
MY161416A (en)	2009-05-22	2017-04-14	Incyte Holdings Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
KR101771401B1 (ko)	2009-05-22	2017-08-25	인사이트 홀딩스 코포레이션	야누스 키나제 억제제로서 피라졸４일피롤로［２,３ｄ］피리미딘 및 피롤３일피롤로［２,３ｄ］피리미딘의 Ｎ(헤테로)아릴피롤리딘 유도체
SI2442809T1 (sl)	2009-06-17	2017-01-31	Vertex Pharmaceuticals Incorporated	Inhibitorji replikacije virusov gripe
WO2011012283A1 (en) *	2009-07-30	2011-02-03	University Of Zurich	Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR101805936B1 (ko)	2009-10-09	2017-12-07	인사이트 홀딩스 코포레이션	3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
AU2010308028A1 (en)	2009-10-15	2012-04-19	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
AR078833A1 (es) *	2009-10-29	2011-12-07	Palau Pharma Sa	Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3
JP5739446B2 (ja)	2009-12-18	2015-06-24	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物
EP2528916A1 (en) *	2010-01-27	2012-12-05	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
WO2011094273A1 (en) *	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
TWI850648B (zh)	2010-03-10	2024-08-01	美商英塞特控股公司	作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
MY178634A (en)	2010-05-21	2020-10-19	Incyte Corp	Topical formulation for a jak inhibitor
SA111320519B1 (ar)	2010-06-11	2014-07-02	Astrazeneca Ab	مركبات بيريميدينيل للاستخدام كمثبطات atr
PH12013501001A1 (en)	2010-11-19	2019-09-02	Incyte Holdings Corp	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2818545C (en)	2010-11-19	2019-04-16	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR20130128435A (ko) *	2010-12-16	2013-11-26	버텍스 파마슈티칼스 인코포레이티드	인플루엔자 바이러스 복제의 억제제
WO2012083117A1 (en)	2010-12-16	2012-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
EP2675451B9 (en)	2011-02-18	2017-07-26	Novartis Pharma AG	mTOR/JAK INHIBITOR COMBINATION THERAPY
TWI577676B (zh)	2011-06-20	2017-04-11	英塞特控股公司	作為ｊａｋ抑制劑之吖丁啶基苯基、吡啶基或吡基羧醯胺衍生物
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
WO2013023119A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
WO2013085802A1 (en) *	2011-12-06	2013-06-13	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2014013014A1 (en)	2012-07-18	2014-01-23	Fundació Privada Centre De Regulació Genòmica (Crg)	Jak inhibitors for activation of epidermal stem cell populations
HUE055894T2 (hu)	2012-11-15	2021-12-28	Incyte Holdings Corp	A ruxolitinib nyújtott felszabadulású dózisformái
RS62867B1 (sr)	2013-03-06	2022-02-28	Incyte Holdings Corp	Postupci i intermedijeri za dobijanje inhibitora jak
WO2014145576A2 (en)	2013-03-15	2014-09-18	Northwestern University	Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CR20190343A (es)	2013-08-07	2019-10-02	Incyte Corp	FORMAS DE DOSIFICACIÓN DE LIBERACIÓN PROLONGADA PARA UN INHIBIDOR DE JAK 1 (Divisional de Exp: 2016-0102)
MX382171B (es)	2013-11-13	2025-03-13	Vertex Pharmaceuticals Incorporated	Inhibidores de replicacion del virus de influenza.
AU2014348752C1 (en)	2013-11-13	2019-11-21	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
AR101196A1 (es)	2014-07-16	2016-11-30	Gruenenthal Gmbh	Compuestos de pirimidina sustituidos
AR101197A1 (es) *	2014-07-16	2016-11-30	Gruenenthal Gmbh	Pirimidinas 2,5-sustituidas
AR101198A1 (es)	2014-07-16	2016-11-30	Gruenenthal Gmbh	Pirimidinas 2,5-sustituidas como inhibidores de pde4b
TWI679205B (zh) *	2014-09-02	2019-12-11	日商日本新藥股份有限公司	吡唑并噻唑化合物及醫藥
CA2957475A1 (en) *	2014-09-08	2016-03-17	Janssen Sciences Ireland Uc	Pyrrolopyrimidines for use in influenza virus infection
WO2016183116A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
MA42422A (fr)	2015-05-13	2018-05-23	Vertex Pharma	Inhibiteurs de la réplication des virus de la grippe
CA3005514A1 (en)	2015-11-27	2017-06-01	Janssen Sciences Ireland Uc	Heterocyclic indoles for use in influenza virus infection
KR20180100375A (ko)	2016-01-20	2018-09-10	얀센 사이언시즈 아일랜드 유씨	인플루엔자 바이러스 감염에서 사용하기 위한 아릴 치환 피리미딘
WO2017133669A1 (en) *	2016-02-05	2017-08-10	Savira Pharmaceuticals Gmbh	5, 7-diazaindole and 5, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
TWI712604B (zh) *	2016-03-01	2020-12-11	日商日本新藥股份有限公司	具jak抑制作用之化合物之結晶
EP3452477B1 (en) *	2016-05-04	2023-09-13	B.C.I. Pharma	Adenine derivatives as protein kinase inhibitors
CN109843883B (zh) *	2016-07-26	2022-01-14	苏州隆博泰药业有限公司	作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
WO2018041989A1 (en)	2016-09-02	2018-03-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating refractory celiac disease type 2
EA039352B1 (ru) *	2017-01-19	2022-01-17	Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд.	Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение
WO2018157830A1 (en) *	2017-03-02	2018-09-07	Sunshine Lake Pharma Co., Ltd.	Inhibitors of influenza virus replication and uses thereof
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
HRP20220510T1 (hr)	2018-01-30	2022-05-27	Incyte Corporation	Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
FI3773593T3 (fi)	2018-03-30	2024-06-18	Incyte Corp	Hidradenitis suppurativan hoito jak-estäjiä käyttäen
CN109293640B (zh) *	2018-10-31	2020-05-19	青岛清原化合物有限公司	一种取代的含氮杂芳环甲酰胺衍生物及其除草组合物和用途
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en)	2019-04-16	2020-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
MX2021013602A (es)	2019-05-08	2022-04-06	Vimalan Biosciences Inc	Inhibidores de jak.
TW202122400A (zh)	2019-08-08	2021-06-16	美商維瑪蘭生物科學公司	Jak抑制劑
JP2022549435A (ja) *	2019-09-25	2022-11-25	ビマランバイオサイエンシーズ，インク．	Ｊａｋ阻害剤
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2023222565A1 (en)	2022-05-16	2023-11-23	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5716981A (en)	1993-07-19	1998-02-10	Angiogenesis Technologies, Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
HUP0001507A3 (en) *	1997-03-19	2002-01-28	Abbott Gmbh & Co Kg	Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
IL139586A0 (en) *	1998-06-19	2002-02-10	Pfizer Prod Inc	PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
GB0308466D0 (en) *	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
TWI339206B (en) *	2003-09-04	2011-03-21	Vertex Pharma	Compositions useful as inhibitors of protein kinases
JP2007514759A (ja) *	2003-12-19	2007-06-07	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
US20050165029A1 (en) *	2004-01-13	2005-07-28	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases

2006
- 2006-09-28 RU RU2008117151/04A patent/RU2008117151A/ru not_active Application Discontinuation
- 2006-09-28 WO PCT/US2006/037593 patent/WO2007041130A2/en active Application Filing
- 2006-09-28 EP EP12175875A patent/EP2532667A1/en not_active Withdrawn
- 2006-09-28 KR KR1020087010531A patent/KR20080063809A/ko not_active Application Discontinuation
- 2006-09-28 CA CA002623032A patent/CA2623032A1/en not_active Abandoned
- 2006-09-28 JP JP2008533551A patent/JP2009513571A/ja active Pending
- 2006-09-28 ZA ZA200802685A patent/ZA200802685B/xx unknown
- 2006-09-28 EP EP06815526A patent/EP1931674B1/en active Active
- 2006-09-28 US US11/528,779 patent/US8580802B2/en not_active Expired - Fee Related
- 2006-09-28 ES ES06815526T patent/ES2401192T3/es active Active
- 2006-09-28 SG SG200902181-7A patent/SG151327A1/en unknown
- 2006-09-28 AU AU2006297351A patent/AU2006297351A1/en not_active Abandoned
- 2006-09-28 CN CN200680039592A patent/CN101801971A/zh active Pending
- 2006-09-28 NZ NZ567133A patent/NZ567133A/xx not_active IP Right Cessation
2008
- 2008-03-18 IL IL190249A patent/IL190249A0/en unknown
- 2008-04-29 NO NO20082026A patent/NO20082026L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200802685B (en)	2009-10-28
EP1931674A2 (en)	2008-06-18
WO2007041130A2 (en)	2007-04-12
JP2009513571A (ja)	2009-04-02
SG151327A1 (en)	2009-04-30
CN101801971A (zh)	2010-08-11
KR20080063809A (ko)	2008-07-07
NZ567133A (en)	2011-07-29
US20070207995A1 (en)	2007-09-06
ES2401192T8 (es)	2013-05-10
IL190249A0 (en)	2008-11-03
WO2007041130A3 (en)	2010-01-21
US8580802B2 (en)	2013-11-12
CA2623032A1 (en)	2007-04-12
RU2008117151A (ru)	2009-11-10
EP2532667A1 (en)	2012-12-12
ES2401192T3 (es)	2013-04-17
EP1931674B1 (en)	2012-12-12
AU2006297351A1 (en)	2007-04-12

Publication	Publication Date	Title
NO20082026L (no)	2008-06-25	Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20083501L (no)	2008-10-14	Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
NO20074431L (no)	2007-08-31	Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
NO20084747L (no)	2008-11-25	Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20065727L (no)	2006-12-12	Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
MX2009010127A (es)	2009-11-05	Compuestos utiles como inhibidores de janus cinasas.
NO20073140L (no)	2007-06-20	Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20073628L (no)	2007-07-16	Pyridoner som er nyttige som inhibitorer av kinaser
NO20052595L (no)	2005-06-27	Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
MXPA06011327A (es)	2006-12-15	Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
NO20083918L (no)	2008-11-12	Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
ATE482213T1 (de)	2010-10-15	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20071915L (no)	2007-05-18	Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
ATE542814T1 (de)	2012-02-15	Pyrazinkinaseinhibitoren
MX2007014619A (es)	2009-02-13	Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20092130L (no)	2009-06-17	Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
ATE466580T1 (de)	2010-05-15	Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de)	2010-06-15	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2007-07-15	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20084435L (no)	2008-11-28	C-MET proteinkinaseinhibitorer
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
NO20072567L (no)	2007-07-17	Triazoler nyttige som proteinkinase-inhibitorer

Legal Events

Date	Code	Title	Description
2013-04-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application